Rebiscan, Inc.
10
1
3
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
10.0%
1 terminated/withdrawn out of 10 trials
85.7%
-0.8% vs industry average
0%
0 trials in Phase 3/4
17%
1 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
HITT for the Identification of Mild Traumatic Brain Injury
Role: lead
mTBI Identification and Monitoring Through Retinal Scanning
Role: lead
Head and Intraocular Trauma Tool for the Identification of Mild Traumatic Brain Injury
Role: lead
Amblyopia and Strabismus Detection Using Retinal Birefringence Imaging
Role: lead
Improving Quality Vision Outcomes in Managed Care Setting While Reducing Cost by Use of Accurate, Automated Screening
Role: lead
Neuro-ocular Baselines in a Sports Setting
Role: lead
HITT Device Pilot Testing for Traumatic Brain Injury
Role: lead
Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner
Role: lead
Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner
Role: lead
Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner
Role: lead
All 10 trials loaded